Indication
Treatment of sickle cell disease (SCD) in patients 12 years of age and older with recurrent vaso-occlusive crises (VOCs) who have βS/βS, βS/β0 or βS/β+, for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen (HLA)-matched related HSC donor is not available.
Medicine details
- Medicine name:
- exagamglogene autotemcel (Casgevy)
- SMC ID:
- SMC2852
- Pharmaceutical company
- Vertex Pharmaceuticals Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 12 January 2026
- SMC meeting date:
- 02 December 2025
- Patient group submission deadline:
- 06 October 2025